questionsmedicales.fr
Acides aminés, peptides et protéines
Protéines
Protéines membranaires
Glycoprotéines membranaires
Protéines liées au GPI
Carbonic anhydrase-IV
Carbonic anhydrase-IV : Questions médicales fréquentes
Termes MeSH sélectionnés :
Programmed Cell Death 1 Receptor
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Carbonic anhydrase-IV : Questions médicales les plus fréquentes",
"headline": "Carbonic anhydrase-IV : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Carbonic anhydrase-IV : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-15",
"dateModified": "2025-04-11",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Carbonic anhydrase-IV"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Protéines liées au GPI",
"url": "https://questionsmedicales.fr/mesh/D058851",
"about": {
"@type": "MedicalCondition",
"name": "Protéines liées au GPI",
"code": {
"@type": "MedicalCode",
"code": "D058851",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.543.550.418"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Carbonic anhydrase-IV",
"alternateName": "Carbonic Anhydrase IV",
"code": {
"@type": "MedicalCode",
"code": "D030741",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Claudiu T Supuran",
"url": "https://questionsmedicales.fr/author/Claudiu%20T%20Supuran",
"affiliation": {
"@type": "Organization",
"name": "Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), Pharmaceutical and Nutraceutical Sciences Section, University of Florence, Via Ugo Schiff 6, 50019 Florence, Italy."
}
},
{
"@type": "Person",
"name": "Andrea Angeli",
"url": "https://questionsmedicales.fr/author/Andrea%20Angeli",
"affiliation": {
"@type": "Organization",
"name": "Department of Neurosciences, Psychology, Drug Research and Child Health, Pharmaceutical and Nutraceutical Section, University of Florence, Sesto Fiorentino, Italy."
}
},
{
"@type": "Person",
"name": "Alessio Nocentini",
"url": "https://questionsmedicales.fr/author/Alessio%20Nocentini",
"affiliation": {
"@type": "Organization",
"name": "Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), Pharmaceutical and Nutraceutical Sciences Section, University of Florence, Via Ugo Schiff 6, 50019 Florence, Italy."
}
},
{
"@type": "Person",
"name": "Clemente Capasso",
"url": "https://questionsmedicales.fr/author/Clemente%20Capasso",
"affiliation": {
"@type": "Organization",
"name": "Istituto di Bioscienze e Biorisorse - Consiglio Nazionale delle Ricerche CNR, Via P: Castellino 111, 80131, Naples, Italy."
}
},
{
"@type": "Person",
"name": "Marta Ferraroni",
"url": "https://questionsmedicales.fr/author/Marta%20Ferraroni",
"affiliation": {
"@type": "Organization",
"name": "University of Florence, Department of Chemistry, via della Lastruccia, 50019 Sesto Fiorentino, Italy."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Decoding the genetic links between serum lipidomic profile, amino acid biomarkers, and programmed cell death protein-1/programmed cell death-ligand-1.",
"datePublished": "2023-07-27",
"url": "https://questionsmedicales.fr/article/37498324",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00262-023-03501-8"
}
},
{
"@type": "ScholarlyArticle",
"name": "C2-Symmetrical Terphenyl Derivatives as Small Molecule Inhibitors of Programmed Cell Death 1/Programmed Death Ligand 1 Protein-Protein Interaction.",
"datePublished": "2024-06-04",
"url": "https://questionsmedicales.fr/article/38893521",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/molecules29112646"
}
},
{
"@type": "ScholarlyArticle",
"name": "The prognostic value of tumour-infiltrating lymphocytes, programmed cell death protein-1 and programmed cell death ligand-1 in Stage I-III triple-negative breast cancer.",
"datePublished": "2023-03-25",
"url": "https://questionsmedicales.fr/article/36966236",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41416-023-02218-w"
}
},
{
"@type": "ScholarlyArticle",
"name": "Programmed Cell Death-1 (PD-1) anchoring to the GPI-linked co-receptor CD48 reveals a novel mechanism to modulate PD-1-dependent inhibition of human T cells.",
"datePublished": "2023-03-06",
"url": "https://questionsmedicales.fr/article/36889184",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.molimm.2023.02.007"
}
},
{
"@type": "ScholarlyArticle",
"name": "Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed death-ligand 1 inhibitors in non-small cell lung cancer.",
"datePublished": "2023-02-27",
"url": "https://questionsmedicales.fr/article/36848319",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/cncr.34683"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Protéines membranaires",
"item": "https://questionsmedicales.fr/mesh/D008565"
},
{
"@type": "ListItem",
"position": 5,
"name": "Glycoprotéines membranaires",
"item": "https://questionsmedicales.fr/mesh/D008562"
},
{
"@type": "ListItem",
"position": 6,
"name": "Protéines liées au GPI",
"item": "https://questionsmedicales.fr/mesh/D058851"
},
{
"@type": "ListItem",
"position": 7,
"name": "Carbonic anhydrase-IV",
"item": "https://questionsmedicales.fr/mesh/D030741"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Carbonic anhydrase-IV - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Carbonic anhydrase-IV",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-18",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Carbonic anhydrase-IV",
"description": "Comment diagnostiquer une déficience en anhydrase carbonique IV ?\nQuels examens sont utilisés pour évaluer l'activité de l'enzyme ?\nQuels symptômes peuvent indiquer un problème avec l'enzyme ?\nY a-t-il des marqueurs biologiques spécifiques ?\nPeut-on utiliser l'imagerie pour le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D030741?mesh_terms=Programmed+Cell+Death+1+Receptor&page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Carbonic anhydrase-IV",
"description": "Quels sont les symptômes d'une déficience en anhydrase carbonique IV ?\nComment se manifestent les troubles respiratoires ?\nY a-t-il des symptômes neurologiques associés ?\nLes calculs rénaux sont-ils un symptôme courant ?\nPeut-on observer des symptômes digestifs ?",
"url": "https://questionsmedicales.fr/mesh/D030741?mesh_terms=Programmed+Cell+Death+1+Receptor&page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Carbonic anhydrase-IV",
"description": "Peut-on prévenir la déficience en anhydrase carbonique IV ?\nY a-t-il des mesures préventives pour les calculs rénaux ?\nLes tests génétiques peuvent-ils aider à la prévention ?\nDes conseils diététiques peuvent-ils prévenir les symptômes ?\nLes activités physiques sont-elles bénéfiques ?",
"url": "https://questionsmedicales.fr/mesh/D030741?mesh_terms=Programmed+Cell+Death+1+Receptor&page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Carbonic anhydrase-IV",
"description": "Quels traitements sont disponibles pour la déficience ?\nLa thérapie génique est-elle une option ?\nComment gérer les symptômes respiratoires ?\nY a-t-il des médicaments spécifiques à éviter ?\nLes changements alimentaires sont-ils recommandés ?",
"url": "https://questionsmedicales.fr/mesh/D030741?mesh_terms=Programmed+Cell+Death+1+Receptor&page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Carbonic anhydrase-IV",
"description": "Quelles complications peuvent survenir avec cette déficience ?\nLes troubles respiratoires peuvent-ils s'aggraver ?\nY a-t-il un risque accru de déshydratation ?\nLes complications neurologiques sont-elles possibles ?\nComment les complications sont-elles gérées ?",
"url": "https://questionsmedicales.fr/mesh/D030741?mesh_terms=Programmed+Cell+Death+1+Receptor&page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Carbonic anhydrase-IV",
"description": "Quels sont les facteurs de risque pour cette déficience ?\nL'âge joue-t-il un rôle dans le risque ?\nLes maladies rénales augmentent-elles le risque ?\nY a-t-il des facteurs environnementaux à considérer ?\nLes habitudes alimentaires peuvent-elles affecter le risque ?",
"url": "https://questionsmedicales.fr/mesh/D030741?mesh_terms=Programmed+Cell+Death+1+Receptor&page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une déficience en anhydrase carbonique IV ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques et des analyses sanguines peuvent confirmer la déficience."
}
},
{
"@type": "Question",
"name": "Quels examens sont utilisés pour évaluer l'activité de l'enzyme ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests enzymatiques dans des échantillons de sang ou de tissus sont utilisés."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un problème avec l'enzyme ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme la déshydratation, des troubles respiratoires ou des calculs rénaux peuvent survenir."
}
},
{
"@type": "Question",
"name": "Y a-t-il des marqueurs biologiques spécifiques ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux anormaux de bicarbonate dans le sang peuvent indiquer un dysfonctionnement."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser l'imagerie pour le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'imagerie peut aider à évaluer les complications, mais n'est pas spécifique au diagnostic."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une déficience en anhydrase carbonique IV ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent fatigue, déshydratation, et troubles respiratoires."
}
},
{
"@type": "Question",
"name": "Comment se manifestent les troubles respiratoires ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent se manifester par une respiration rapide ou des difficultés à respirer."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes neurologiques associés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des maux de tête et des troubles de la concentration peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les calculs rénaux sont-ils un symptôme courant ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la formation de calculs rénaux est fréquente en cas de déficience."
}
},
{
"@type": "Question",
"name": "Peut-on observer des symptômes digestifs ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des nausées et des vomissements peuvent également être présents."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir la déficience en anhydrase carbonique IV ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention est difficile, mais un diagnostic précoce peut aider à gérer les symptômes."
}
},
{
"@type": "Question",
"name": "Y a-t-il des mesures préventives pour les calculs rénaux ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Boire beaucoup d'eau et réduire l'apport en sel peut aider à prévenir les calculs."
}
},
{
"@type": "Question",
"name": "Les tests génétiques peuvent-ils aider à la prévention ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les tests génétiques peuvent identifier les personnes à risque."
}
},
{
"@type": "Question",
"name": "Des conseils diététiques peuvent-ils prévenir les symptômes ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation équilibrée peut réduire les symptômes associés."
}
},
{
"@type": "Question",
"name": "Les activités physiques sont-elles bénéfiques ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une activité physique modérée peut améliorer la santé générale et le bien-être."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour la déficience ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des suppléments de bicarbonate et une hydratation adéquate."
}
},
{
"@type": "Question",
"name": "La thérapie génique est-elle une option ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La thérapie génique est en recherche, mais pas encore disponible pour cette condition."
}
},
{
"@type": "Question",
"name": "Comment gérer les symptômes respiratoires ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des bronchodilatateurs peuvent être prescrits pour améliorer la respiration."
}
},
{
"@type": "Question",
"name": "Y a-t-il des médicaments spécifiques à éviter ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains diurétiques peuvent aggraver les symptômes et doivent être évités."
}
},
{
"@type": "Question",
"name": "Les changements alimentaires sont-ils recommandés ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation riche en liquides et faible en sodium est souvent conseillée."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec cette déficience ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme l'acidose métabolique et des troubles rénaux peuvent se produire."
}
},
{
"@type": "Question",
"name": "Les troubles respiratoires peuvent-ils s'aggraver ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, sans traitement, les troubles respiratoires peuvent devenir graves."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque accru de déshydratation ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les patients peuvent être plus susceptibles de souffrir de déshydratation."
}
},
{
"@type": "Question",
"name": "Les complications neurologiques sont-elles possibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des complications neurologiques comme des convulsions peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment les complications sont-elles gérées ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion des complications nécessite un suivi médical régulier et des traitements adaptés."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour cette déficience ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents familiaux et certaines mutations génétiques augmentent le risque."
}
},
{
"@type": "Question",
"name": "L'âge joue-t-il un rôle dans le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines formes de déficience peuvent se manifester dès l'enfance."
}
},
{
"@type": "Question",
"name": "Les maladies rénales augmentent-elles le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les maladies rénales préexistantes peuvent exacerber les symptômes."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs environnementaux à considérer ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines expositions environnementales peuvent influencer le risque de déficience."
}
},
{
"@type": "Question",
"name": "Les habitudes alimentaires peuvent-elles affecter le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation déséquilibrée peut contribuer à des complications."
}
}
]
}
]
}
Disruptions in lipid metabolism and amino acids have been increasingly linked to resistance to immunotherapy. However, the underlying mechanisms by which dysregulated serum lipid metabolism and amino ...
To elucidate the potential associations between lipid metabolism, amino acids, and PD-1/PD-L1, we employed the powerful Mendelian randomization (MR) method, leveraging large-scale genome-wide associat...
In the present MR study, we identified a noteworthy negative association between alanine and PD-1 expression, implicating a regulatory role for alanine metabolism in modulating the immune response to ...
These findings provided new insights into the role of lipid metabolism as well as amino acids in regulating PD-1/PD-L1, suggesting that strategies targeting lipid and amino acid metabolisms may have t...
The PD-1/PD-L1 complex is an immune checkpoint responsible for regulating the natural immune response, but also allows tumors to escape immune surveillance. Inhibition of the PD-1/PD-L1 axis positivel...
Tumour-infiltrating lymphocytes (TILs) represent a robust biological prognostic biomarker in triple-negative breast cancer (TNBC); however, the contribution of different subsets of immune cells is unc...
In total, 259 patients with Stage I-III TNBC were reviewed. The density of sTILs along with the presence of total (t), stromal (s), and intratumoral (i) CD8...
All immune markers were positively correlated with each other (P < 0.05). In the multivariate analysis, sTILs (P = 0.046), tCD8...
In addition to sTILs, inclusion of tCD8...
Activation of PD-1 by anchoring it to Antigen Receptor (AR) components or associated co-receptors represents an attractive approach to treat autoimmune conditions. In this study, we provide evidence t...
The availability of agents targeting the programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) immune checkpoint has transformed treatment of advanced and/or metastatic non-small ce...
To study the expression of the programmed cell death receptor (PD-1) and its ligand (PD-L1) by immunocompetent cells in endometrial cancer patients with metabolic disorders....
Populations and subpopulations of lymphocytes were analyzed by flow cytometry. Antibodies against CD279 were used to detect PD-1 on the CD4+ and CD8+ T cells. Antibodies against CD14 and CD274 were us...
In patients with severe metabolic disorders, the expression of PD-1 on CD8+ and CD4+ lymphocytes and the expression of the corresponding PD-L1 on CD14+ cells before treatment and after radiation thera...
Theincreased expression of PD-1 and PD-L1 receptors by immunocompetent cells can be considered a new prognostic marker in endometrial cancer patients with morbid obesity....
Programmed Cell Death-1 (PCD-1) is a key immune checkpoint receptor, which mainly expresses on activated T, B, Dendritic (DC), Natural Killer (NK), and Treg cells. On the surface of activated T-cells,...
Programmed death receptor 1 (PD-1) inhibition has shown durable response and mild adverse events (AEs) in adult malignancies. However, data on the clinical activity of PD-1 inhibition in pediatric pat...
We conducted a real-world, multi-institutional, retrospective analysis of pediatric malignancies treated with PD-1 inhibitor-based regimens. The primary endpoints were objective response rate (ORR) an...
A total of 93 and 109 patients were evaluated for efficacy and safety, respectively. For all efficacy-evaluable patients, PD-1 inhibitor monotherapy, combined chemotherapy, combined histone deacetylas...
This largest retrospective analysis demonstrate that PD-1 inhibitor-based regimens are potentially effective and tolerable in pediatric malignancies. Our findings provide references for future clinica...
Patients with traumatic brain injury (TBI) frequently exhibit concomitant immunosuppression. In this study, we evaluated the predictive values of soluble programmed death-1 (sPD-1) and soluble program...
Combined chemoradiotherapy (CRT) and programmed cell death-ligand 1 (PD-L1) blockade is a new care standard for unresectable stage III non-small-cell lung cancer (NSCLC). Although this consolidation t...